FGFR1 and neoplasm: Considering the high expression levels of FGFR1 and FGFR3 across all EPN subtypes as well as the FGFR-driven malignant phenotype of ST-RELA and PF-A tumor cells, we tested the sensitivity of EPN cells towards a panel of small molecule FGFR tyrosine kinase inhibitors (FGFRi).